XOMA
NASDAQ · Biotechnology
Xoma Royalty Corporation
$40.17
-4.05 (-9.16%)
Financial Highlights (FY 2026)
Revenue
51.27M
Net Income
31.18M
Gross Margin
100.0%
Profit Margin
60.8%
Rev Growth
+105.3%
D/E Ratio
1.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 35.3% | 35.3% |
| Operating Margin | 62.5% | -65.3% | -4.3% | -4.2% |
| Profit Margin | 60.8% | -46.1% | -5.4% | -5.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 51.27M | 33.35M | 45.56M | 48.20M |
| Gross Profit | 51.27M | 33.35M | 16.09M | 17.03M |
| Operating Income | 32.06M | -21,769,027 | -1,958,591 | -2,016,421 |
| Net Income | 31.18M | -14,563,878 | -2,452,418 | -2,537,562 |
| Gross Margin | 100.0% | 100.0% | 35.3% | 35.3% |
| Operating Margin | 62.5% | -65.3% | -4.3% | -4.2% |
| Profit Margin | 60.8% | -46.1% | -5.4% | -5.3% |
| Rev Growth | +105.3% | -9.3% | +14.7% | +11.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 181.73M | 95.71M | 89.27M | 94.75M |
| Total Equity | 173.35M | 66.29M | 241.93M | 256.04M |
| D/E Ratio | 1.05 | 1.44 | 0.37 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 34.97M | -22,420,452 | -2,902,540 | -2,951,728 |
| Free Cash Flow | — | — | -1,967,070 | -1,836,225 |